Browse by Medical Category
The Vasculitis and Glomerulonephritis Center at Massachusetts General Hospital combines the expertise of specialists from the Divisions of Rheumatology and Nephrology to provide individualized, high-quality care to patients with vasculitis, glomerulonephritis and more than 30 related conditions. Our team of experts is dedicated to excellence in patient care through early diagnosis, personalized treatment and leading-edge research in vasculitis, glomerulonephritis and related conditions.
An individual's diagnosis—in particular, the severity of the disease and the extent that organs are affected—will determine the prognosis and treatment plan. With early diagnosis and expert management, many patients can expect to maintain long-term remission of vasculitis and glomerulonephritis. In order to maximize the effectiveness of treatment and to minimize medication side effects, our approach relies on developing a personalized treatment plan for each patient.
Our center provides patients with one access point to a core group of specialists who have extensive experience in treating patients with vasculitis and glomerulonephritis. As necessary, we will coordinate care with our team of subspecialty experts, including:
The diagnosis and treatment of vasculitis and glomerulonephritis requires a careful review of a patient’s symptoms and previous testing. During a patient’s first appointment at the Mass General Vasculitis and Glomerulonephritis Center, we will review his/her medical history, perform a physical examination and decide what additional tests are necessary to make an accurate diagnosis. We will also conduct a careful review of the patient’s medical records, therefore we ask all patients to bring their medical notes, as well as related test results and biopsy samples.
An important component to leading-edge patient care is the development of new diagnostic tools and effective treatment strategies. Our physicians have led a number of studies that have helped establish the current standard of treatment in the diagnosis and treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis and Giant Cell Arteritis. Our patients have access to ongoing clinical trials in treatment for several types of vasculitis and glomerulonephritis.
Not Accepting New Patients
Accepting New Patients
Accepting New Patients - Call for Availability
The Vasculitis and Glomerulonephritis Center cares for more than 30 conditions related to vasculitis and glomerulonephritis.
Glomerulonephritis is a type of glomerular kidney disease in which the kidneys' filters become inflamed and scarred, and slowly lose their ability to remove wastes and excess fluid from the blood to make urine.
Vasculitis refers to a group of diseases that result in inflammation, or swelling, of blood vessels. The inflammation damages the vessels, thus affecting the organs supplied by these blood vessels.
For more information on enrolling in a clinical trial, please speak to a member of your Mass General care team or contact us at 617-726-0738.
The Vasculitis and Glomerulonephritis Center at Massachusetts General Hospital is dedicated to improving the treatment of vasculitis and glomerulonephritis through leading-edge research. Our physicians are engaged in research studies ranging from understanding the biology of vasculitis through laboratory-based research to testing new treatments in clinical trials.
We are actively enrolling patients in the following research studies:
More alternatives to control Giant Cell Arteritis and decrease the usual prolonged exposure to prednisone are needed. This trial examines whether 12 months of ustekinumab, in combination with only 6 months of prednisone, is effective in keeping Giant Cell Arteritis in remission. Shorted prednisone tapers will likely result in less prednisone-related side effects.
Recent studies have demonstrated that rituximab therapy may be effective in some patients with ANCA-associated vasculitis, however the optimal duration of treatment remains unknown. This study is currently enrolling patients who have received rituximab for 18 months or longer to determine the most effective strategy for reducing the rituximab dose while keeping vasculitis under good control.
This is a phase III, multi-center, randomized, double-blind, placebo-controlled trial to assess the use of the investigational drug Avacopan in patients with newly diagnosed or relapsing ANCA-associated vasculitis (AAV). This trial will determine if Avacopan can induce and sustain remission in patients with AAV, when used in combination with Rituximab, or Cyclophosphamide and Azathioprine.
There is currently no standardized treatment for C3 Glomerulopathy. This trial examines the safety and efficacy of the investigational drug Avacopan in patients with C3 Glomerulopathy. This is a phase II, multi-center, randomized, double-blind, placebo-controlled study.
In previous trials, treatment with the investigational drug CCX140-B has been shown to reduce proteinuria in patients with diabetic nephropathy. This study aims to determine if CCX140-B can also be effective in reducing proteinuria in patients with primary FSGS. This is a multi-center, randomized, double-blind, placebo-controlled, dose ranging study.
We have two locations at Massachusetts General Hospital. If you are scheduling an appointment, our staff will confirm at which location your appointment will be held.
Suite 4FBoston, MA 02144 See Maps & Directions
Boston, MA 02114 See Maps & Directions
Back to Top